Kornimate/medical-research-clean huggingface dataset:
evaluation of a question prompt list for patients with myelodysplastic syndromes (qpl-mds)

Conditions: Myelodysplastic Syndromes

Summary: mds are a diverse group of hematopoietic malignancies, which mainly occur in patients over 75 years of age. incidence rate in 2012 in france was more than 6 cases per 100 000 person-years. mds are characterized by ineffective haematopoiesis causing cytopenia, and by leukemic transformation. the disease is heterogeneous, its pathophysiology complex and clinical evolution variable.the few data available on mds patients show how difficult it is to understand mds, its prognosis and the reasons for prescribing or not some treatments. in the context of a highly complex potentially lethal disease such as mds, it is of utmost importance to optimize the information conveyed to patients. particularly, 70.5% of mds patients surveyed in our developmental study would have preferred more information about prognosis at diagnosis disclosure. a simple intervention based on the use of a question prompt list (qpl), would greatly improve the information process by helping patients to express their main concerns at their medical consultations. cultural differences may exist in the appraisal of qpls and qpls have not yet been widely used in france. however, in line with the previous results available in the literature and in a context a priori favourable to the use of such an instrument, the investigators hypothesise that use of a qpl will increase mds patients' expressions of concerns and questions at their medical consultations. particularly the investigators assume that the discussion about prognosis will be facilitated, without increasing anxiety because patients remain free to ask or not for such information. the use of qpls would also be a way to limit social inequalities related to insufficient information and to encourage patient-doctor communication and meeting of patient preferences which could lead to better health outcomes.


Eligibility criteria:
inclusion criteria: * patients newly referred for a mds in one of the participating centres * older than 18 * able to answer a self-administered questionnaire * having signed an informed consent * affiliated to the french social security system exclusion criteria: * emergency,patients deprived of liberty or placed under the authority of a tutor
treating alzheimer's and dementia with d-ribose

Conditions: Alzheimers; Dementia

Summary: to study the effectiveness of d-ribose in treating alzheimer's and dementia

clinical experience and the pathophysiology of alzheimer's, including neuronal insulin resistance, suggests that ribose improves clinical outcomes. this study will add ribose 5 gm 3 x day for 8 weeks to monitor outcomes in a pilot study.

Eligibility criteria:
inclusion criteria: * a diagnosis of alzheimer's and/or dementia with a mini mental status exam ( mmse) score over 12 or being ambulatory and able to travel outside the home with assistance. * must have a caregiver living with them. exclusion criteria: * overt and severe causes of secondary dementia such as metastatic brain cancers, or severe overt infectious encephalopathies or severe autoimmune illness. * also, severe life threatening illnesses which would make them unlikely to be alive after 6-12 months.
plasmapheresis versus plasma infusion from young apoe3 homozygotes into mci apoe4 homozygotes to slow disease progression

Conditions: Mild Cognitive Impairment

Summary: determine safety of plasma infusion or exchange in apoe 44 patients.


Eligibility criteria:
inclusion criteria * patient age 50 to 75. * apoe 44 homozygote. * meets the petersen criteria for mci (41). * clinical dementia rating (cdr) of 0.5 and mini mental status examination (mmse) of 24 to 30 inclusive. * has an informant who the investigator judges has sufficient patient contact to provide accurate information. * stable depression and or anxiety. * stable psychoactive medication for 6 weeks. exclusion criteria * history of severe reaction to plasma or plasma derived products which include but not limited to severe allergic reaction, anaphylactic reaction and transfusion related acute lung injury (trali). * patients who do not want to receive blood transfusion for religious or cultural reasons such as jehovah witness faith. * has a medical condition that would interfere with participation such as congestive heart failure (new york heart association class iii or iv), unstable angina, moderate to severe renal impairment, liver failure, and poorly controlled diabetes. * history of autoimmune disease considered clinically significant or requiring chronic steroid or immune suppression medication. * history of being hiv +. * history of +ve test result indicating active hepatitis c or b (defined as both hepatitis b surface antigen and hepatitis core antibody +ve). * uncontrolled hypertension as defined by systolic/diastolic bp three times more than 165/100. * no venous access for plasma exchange therapy. * any neurological condition that could be contributing to cognitive decline such as lewy body disease, front temporal dementia, strokes or other cerebrovascular disease, head trauma, substance abuse, multiple sclerosis, vitamin b12 deficiency, thyroid deficiency. * epileptic seizures within 10 years of screening. * cancer diagnosis (other than non-melanoma skin cancer) in the last 5 years. * more than 1 subcortical stroke or more than 1 cortical stroke. * unable to have an mri. * mri showing acute or subacute hemorrhage, evidence of normal pressure hydrocephalus, hemispheric infarcts, glioma or other brain tumor that could contribute to cognitive decline. * unstable psychiatric condition. * on another experimental treatment study or has been on one in the last 3 months. * if a patient consents to lumbar puncture (lp), they will be excluded from lp if any contraindication to having an lp is present. examples are platelet count\<100,000, spine deformity or contraindication to come off blood thinner for the lp. patients may still participate in the rest of the study without having and lp. * any unspecified reason that the investigator finds the patient unsuitable to take part.
health-promoting competence, coping and quality of life in patients with copd

Conditions: COPD; Coping; Quality of Life

Summary: chronic obstructive pulmonary disease (copd) is a major cause of mortality and disability, and by 2020, it is expected to be the third leading cause of mortality worldwide. copd is a major public health concern and has considerable impact on health and quality of life. for this study an evidence based self-management program is developed, the purpose of the study is to see if this self-management program, in collaboration between specialized health services and municipality health services, improves patients with copd health-promoting competence, coping and quality of life, and reduces health service costs.the study has a rct design.


Eligibility criteria:
inclusion criteria: * diagnosis of copd, gold 2-4 * speak and understand norwegian * adult exclusion criteria: -
effect of circuit weight training on functional capacity and quality of life in breast cancer patients

Conditions: Breast Cancer

Summary: the study is aimed at studying the effects of circuit weight training (cwt) on functional capacity and quality of life in breast cancer patients.

breast cancer is the most common cancer among women in egypt causing 22 percent of all cancer-related female deaths. it is the most commonly diagnosed cancer, accounting for nearly a quarter of all cancer cases globally. with improvements in early detection, surgery, and adjuvant therapy for breast cancer, long-term survival and cure are becoming possible. despite providing longer survival with early diagnosis of breast cancer, the treatment leaves sequelae with adverse effects such as influence on functional capacity, fatigue, depression, neuropathic lymphoedema, low immunity, and loss of flexibility. all of these effects end up affecting the quality of life (qol), imbalance, gait dysfunction, and falls may have particularly severe consequences in breast cancer survivors due to comorbidities increasing the risk of fall-related injury, secondary decline in physical activity, and subsequent functional decline. given the profound effects that imbalance, gait dysfunction, and falls have on functional independence, qol, and long-term health and survivorship, the treatment or prevention of these symptoms is an essential component of cancer rehabilitation for all survivors. furthermore, the need for this study is developed from the lack of quantitative knowledge and information in the published studies about the effect of circuit weight training (cwt) on functional capacity and quality of life in breast cancer patients.

Eligibility criteria:
inclusion criteria: * female with age between 35-45. * body mass index (bmi) \< 25. * patients diagnosed with non-metastatic (stage 0-iii) breast cancer. * all patients who are treated by neoadjuvant chemotherapy before surgery. exclusion criteria: * patients diagnosed with cancer metastasis. * patients diagnosed with diseases of the nervous system (parkinson's disease, peripheral nerve palsy) skeletal system (inflammatory diseases, scoliosis \>10 cobb angle), or rheumatic diseases. * patients with any current visual impairment that affected their daily living, vestibular disorder, neurological disorder, cognitive disorder, and any further medical condition that would prohibit them from participating safely.
dacomitinib (pf-00299804) as a single oral agent in selected patients with adenocarcinoma of the lung

Conditions: Carcinoma, Non-small Cell

Summary: this study will explore the safety and efficacy of the oral panher inhibitor pf-00299804 in patients with adenocarcinoma of the lung who are either non-smokers (\<100 cigarette, cigar or pipe lifetime) or former light smokers ( less than 10 pack-years and stopped at least 15 years) or have known egfr activating mutation; or patients with her 2 amplification or mutation.


Eligibility criteria:
inclusion criteria: * advanced adenocarcinoma of lung, measurable disease * non-smoker, or former light (less than 10 pack years and stopped at least 15 years); or * patients with known egfr activating mutation regardless of smoking status * ecog(eastern cooperative oncology group) 0-1. cohort b (select sites only): patients with her2 amplified or her2 mutation-positive nsclc; may have had prior therapy exclusion criteria: * active brain metastases * prior systemic therapy for advanced disease in cohort a only. cohort b can have had any number of prior lines of systemic therapy. * known egfr wild type nsclc

Keywords: lung cancer adenocarcinoma her2
pulmonary rehabilitation in lymphangioleiomyomatosis

Conditions: Lymphangioleiomyomatosis

Summary: lymphangioleiomyomatosis (lam) is a rare disease in which reduced exercise capacity is frequently present. the mechanisms applied are airflow obstruction, abnormal diffusion capacity and dynamic hyperinflation (dh). pulmonary rehabilitation (pr) has proved benefit in improving exercise tolerance, dyspnea, and quality of life in chronic obstructive pulmonary disease. there are no studies evaluating the impact of pr in patients with lam. the hypothesis under study is that pr determine improvement in exercise capacity, dyspnea, quality of life, muscle force, functional limitation and dh in these patients.


Eligibility criteria:
inclusion criteria: * diagnosis of lymphangioleiomyomatosis established by tissue biopsy and / or a combination of history and high-resolution computed tomography scanning * clinical stability, defined as no exacerbations or hospitalizations related to the underlying disease for a minimum of 6 weeks and no change in the treatment regimen in the last 3 months * low level of physical activity, defined as patients who walk less than 10 thousand daily steps and / or are not performing regular physical activity for at least 4 months before the start of rehabilitation * signature of the free, prior and informed consent for participation in the study exclusion criteria: * lung transplant recipients * musculoskeletal disorders that would prevent the patient from performing exercise training * severe (nyha iv) or uncontrolled heart disease

Keywords: lymphangioleiomyomatosis rehabilitation exercise
influence of food-intake on desmopressin oral tablets and melt-formulation

Conditions: Enuresis; Polyuria

Summary: alarm-treatment as well as desmopressin, a synthetic analogue of human vasopressin, are considered the only evidence-based medicine (ebm) ia treatments in monosymptomatic nocturnal enuresis (mne). desmopressin exists in three different formulations for ambulant use: nasal spray, tablet and lyophilisate (melt) each with differences in bioavailability (spray 2%, tablet 0.2%, melt 0.5%). there 's insufficient evidence to confirm the actually used bioequivalent doses ( 10µg spray = 120µg melt= 0.2mg tablet). although so frequently used, very few pharmacokinetic and -dynamic data on desmopressin are available for children. due to prolonged half life, associated with waterintoxication,the nasal spray has a black box warning from the fda and is no longer recommended . for some authors oral formulations appear to be a safer alternative. however, based on clinical experience of less response rate with oral formulations, lower biodisponibility is suspected. adult research confirms low bioavailability of tablets but also show major influences by food-intake and changes in gastro-intestinal motility. to achieve maximum efficacy, recommendations are to take desmopressin tablet 1 hour before bedtime and 2 hours after meal: this is unrealistic in schoolaged children since there never is 3 hours between evening meal and bedtime. in 2005 a dose response study demonstrated superior pharmaco-kinetic and dynamic properties for desmopressin lyophilisate melt formula. since these results implicate superior action of melt, often a change to melt is recommended if there is a suboptimal response with tablet: sublingual absorption would eliminate the influence of food-intake. however, for this statement there's no evidence, since these tests were all conducted in children in fasting condition. only one clinical study demonstrates bioequivalence for melt and tablet. hypothesis is that desmopressin melt formulation has a better bioavailability when administered together with meal due to its sublingual absorption.


Eligibility criteria:
inclusion criteria: * children aged 6-16 years old * with mne and nocturnal polyuria * treated with desmopressin tablet, non or partial responders, for whom change to melt formulation is indicated according to the international standard guidelines. exclusion criteria: * history of urologic disease, diurnal urinary incontinence, diabetes insipidus, urinary tract infection, clinically significant disease * no systemic use of antibiotics, diuretics, other medication that influences urinary concentrating mechanism * abnormalities of oral mucosa which could influence drugrelease or absorption

Keywords: mne with nocturnal polyuria monosymptomatic nocturnal enuresis with nocturnal polyuria
high dose chemotherapy and autologous transplant for breast cancer

Conditions: Graft vs Host Disease

Summary: to determine survival outcomes for patients with chemosensitive brest cancer after treatment with high dose chemotherapy


Eligibility criteria:
inclusion criteria: * stage ii, iii or iv breast cancer * chemosensitive * adequate organ function exclusion criteria: * prior transplant, * life threatening disease * brain metastases

Keywords: chronic graft vs host disease
detection of asymptomatic atrial fibrillation in persons of 65 year of age or older

Conditions: Atrial Fibrillation

Summary: atrial fibrillation (af) is the most common cardiac arrhythmia. although the condition itself is not life-threatening, the complications result in increased morbidity and mortality. af is often asymptomatic and a considerable number of people suffering from af are not aware of their condition. unfortunately, a cerebral infarction is often the first clinical manifestation. the idea to screen subjects opportunistically for asymptomatic atrial fibrillation (aaf) was infeasible until recently. however, with a recently-developed smartphone connected mobile ecg device (med), this seems to be feasible after all. the main objectives are: * to examine the feasibility of screening subjects of ≥65 years old for aaf. * to validate the smartphone connected med as an aaf screening instrument for application in transmural care in the netherlands.

study design: prospective validation study.

Eligibility criteria:
inclusion criteria: * age ≥65 years * is willing to give informed consent exclusion criteria: * known medical history with atrial fibrillation * not mental competent

Keywords: mobile ecg device asymptomatic atrial fibrillation
establishing lymphedema and fibrosis measures in oral cancer patients

Conditions: Oral Cavity Cancer; Oropharyngeal Cancer; Lymphedema; Fibrosis

Summary: this four-year, prospective, longitudinal study will evaluate and validate a patient-reported outcome measure, clinician-reported outcome measures, and imaging techniques in assessing characteristics, trajectory, and progression of lymphedema and fibrosis (lef) in oral cavity and oropharyngeal cancer patients. this clinical trial studies patient-and-clinician-reported measures as well as standard imaging methods to see how accurate they are in identifying and evaluating lymphedema (swelling) or fibrosis (tough or tight tissue) in the head and neck region of patients receiving treatment for newly diagnosed stage ii-iv oral cavity or oropharyngeal cancer. lymphedema and fibrosis (lef) can lead to physical symptoms, such as trouble swallowing and chewing, as well as psychological and emotional symptoms, such as negative body image and avoiding social interactions. finding an accurate test to identify and evaluate lef may allow doctors to treat lef more quickly and control symptoms more effectively, and thus provide patients with a better quality of life.

the goal of this proposed study is to establish a valid, clinically useful measurement battery for head and neck lef by achieving these specific aims: aim 1: to determine the reliability and validity of the patient-reported outcome measure (lsids-h\&n) for assessing lef-related symptoms in oral cavity and oropharyngeal cancer patients across the trajectory of treatment, recovery, and survival. aim 2: to determine the reliability and validity of the clinician-reported outcome measures (hn-lef grading criteria and modified patterson scale) for assessing external and internal lef in oral cavity and oropharyngeal cancer patients across the trajectory of treatment, recovery, and survival. aim 3: to determine the reliability and validity of imaging techniques (ct scan and ultrasonography) in identifying site-specific lef in oral cavity and oropharyngeal cancer patients across the trajectory of treatment, recovery, and survival.

Eligibility criteria:
inclusion criteria: * a newly diagnosed, histologically proven cancer arising from the oral cavity and oropharynx * tumor stage ii or greater * age ≥ 21 years old * willing and able to undergo study assessment * able to speak and read english and understand informed consent. exclusion criteria: * have medical record documentation of cognitive impairment that would preclude the ability to provide informed consent * are unwilling to undergo routine follow-up * have recurrent cancer * have any other active cancer.
almond supplementation on mild to moderate acne

Conditions: Acne Vulgaris

Summary: this study will assess the effect of almond supplementation on acne and on gut health.


Eligibility criteria:
inclusion criteria: * subjects 15 years of age until 45 years of age. * the presence of mild to moderate acne based on investigator global assessment. * individuals who have remained stable on their topical or oral acne regimen for at least 4 weeks, except if the medication is a noted exclusion. exclusion criteria: * the presence of severe acne as noted by the investigator global assessment. * those with a nut allergy. * those who are unwilling to discontinue oral probiotic-based supplementation to meet the washout criteria prior to enrolling. * those who are unwilling to discontinue topical antibiotics and topical benzoyl peroxide to meet the washout criteria prior to enrolling. * individuals who are unwilling to discontinue vitamin e containing supplements during the washout and intervention. * individuals who have been on an oral antibiotic for acne within the previous 1 month. * individuals who are pregnant or breastfeeding. * individuals who have changed any of their hormonal based contraception within 3 months prior to joining the study. * oral supplementation that has nuts in it. * use of isotretinoin within the three months prior to joining the study. * current tobacco smoker or a tobacco smoking history of greater than 10 pack-years.

Keywords: microbiome nutrition
effectiveness of mobile messenger-initiated reminder on biannual mammography adherence in breast cancer screening

Conditions: Breast Cancer

Summary: female breast cancer is the most common cancer and fifth leading cause of cancer death worldwide. in the past decade, breast cancer consistently to be the most common cancer for women in hong kong, so much that it accounts for 27% of all female cancers, with 4,600 new cases of breast cancer registration every year and the lifetime breast cancer risk for females is 1 in every 14. at the same time, breast cancer ranks the third in cancer death in hong kong, with a five-year relative survival rate of 84%. regular mammography screening has been shown to reduce the mortality of breast cancer. international guidelines recommend annual or biannual mammography screening for women aged 50 or above. the adherence to regular mammography screening remains a challenge. studies had shown that the adherence decreased over time. mailed and telephone reminder were being proven to be effective tools to increase the adherence to regular breast screening using mammography. however, both mailing and telephone strategies are associated with labor intensity and high cost. over the past two decades, the advent of internet and smartphone provided a fertile platform for the development of mobile-health technologies. whatsapp messenger is one of the most frequently used free-of-charge mobile messenger that permits users to send secure messages across different device platforms. a recent randomized controlled trial from our team has suggested its clinical utility in improving adherence to regular colorectal cancer screening using fecal immunochemical test. this encouraging data prompted us to investigate the potential role of whatsapp messenger in breast cancer screening. we hypothesized that text reminder sent via whatsapp messenger improves the longitudinal adherence to biannual mammography in a community-based, opportunistic breast screening program.


Eligibility criteria:
inclusion criteria: * women with negative mammography results which are defined as bi-rads (breast imaging-reporting and data system) 1 or 2 in the first round of mammography screening of the existing opportunistic breast cancer screening cohort * due for second round of biannual follow up of mammography * consented to be contacted via whatsapp messenger exclusion criteria: * those without access to whatsapp messenger or disagreed to be contacted via whatsapp messenger